Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study

被引:18
作者
Neul, Jeffrey L. [1 ]
Benke, Timothy A. [2 ]
Marsh, Eric D. [3 ]
Suter, Bernhard [4 ]
Silveira, Lori [2 ]
Fu, Cary [1 ]
Peters, Sarika U. [1 ]
Percy, Alan K. [5 ]
Rett Syndrome Nat Hist Study Grp
机构
[1] Vanderbilt Univ, Med Ctr, Vanderbilt Kennedy Ctr, Dept Pediat, Nashville, TN 37235 USA
[2] Univ Colorado, Childrens Hosp Colorado, Sch Med, Aurora, CO USA
[3] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA USA
[4] Baylor Coll Med, Houston, TX USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
基金
美国国家卫生研究院;
关键词
Rett syndrome; CDKL5; FOXG1; MECP2; duplication; Neurodevelopmental disorders; Caregiver concerns; SEVERITY; DELINEATION; PHENOTYPES; MUTATIONS; MOUSE; LIFE;
D O I
10.1186/s11689-023-09502-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Recent advances in the understanding of neurodevelopmental disorders such as Rett syndrome (RTT) have enabled the discovery of novel therapeutic approaches that require formal clinical evaluation of efficacy. Clinical trial success depends on outcome measures that assess clinical features that are most impactful for affected individuals. To determine the top concerns in RTT and RTT-related disorders we asked caregivers to list the top caregiver concerns to guide the development and selection of appropriate clinical trial outcome measures for these disorders.Methods Caregivers of participants enrolled in the US Natural History Study of RTT and RTT-related disorders (n = 925) were asked to identify the top 3 concerning problems impacting the affected participant. We generated a weighted list of top caregiver concerns for each of the diagnostic categories and compared results between the disorders. Further, for classic RTT, caregiver concerns were analyzed by age, clinical severity, and common RTT-causing mutations in MECP2.Results The top caregiver concerns for classic RTT were effective communication, seizures, walking/balance issues, lack of hand use, and constipation. The frequency of the top caregiver concerns for classic RTT varied by age, clinical severity, and specific mutations, consistent with known variation in the frequency of clinical features across these domains. Caregivers of participants with increased seizure severity often ranked seizures as the first concern, whereas caregivers of participants without active seizures often ranked hand use or communication as the top concern. Comparison across disorders found commonalities in the top caregiver concerns between classic RTT, atypical RTT, MECP2 duplication syndrome, CDKL5 deficiency disorder, and FOXG1 syndrome; however, distinct differences in caregiver concerns between these disorders are consistent with the relative prevalence and impact of specific clinical features.Conclusion The top caregiver concerns for individuals with RTT and RTT-related disorders reflect the impact of the primary clinical symptoms of these disorders. This work is critical in the development of meaningful therapies, as optimal therapy should address these concerns. Further, outcome measures to be utilized in clinical trials should assess these clinical issues identified as most concerning by caregivers.
引用
收藏
页数:17
相关论文
共 48 条
  • [1] VISUAL IMPAIRMENT IN FOXG1-MUTATED INDIVIDUALS AND MICE
    Boggio, E. M.
    Pancrazi, L.
    Gennaro, M.
    Lo Rizzo, C.
    Mari, F.
    Meloni, I.
    Ariani, F.
    Panighini, A.
    Novelli, E.
    Biagioni, M.
    Strettoi, E.
    Hayek, J.
    Rufa, A.
    Pizzorusso, T.
    Renieri, A.
    Costa, M.
    [J]. NEUROSCIENCE, 2016, 324 : 496 - 508
  • [2] Anxiety-like behavior and anxiolytic treatment in the Rett syndrome natural history study
    Buchanan, Caroline B.
    Stallworth, Jennifer L.
    Joy, Aubin E.
    Dixon, Rebekah E.
    Scott, Alexandra E.
    Beisang, Arthur A.
    Benke, Timothy A.
    Glaze, Daniel G.
    Haas, Richard H.
    Heydemann, Peter T.
    Jones, Mary D.
    Lane, Jane B.
    Lieberman, David N.
    Marsh, Eric D.
    Neul, Jeffrey L.
    Peters, Sarika U.
    Ryther, Robin C.
    Skinner, Steve A.
    Standridge, Shannon M.
    Kaufmann, Walter E.
    Percy, Alan K.
    [J]. JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2022, 14 (01)
  • [3] Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage
    Collins, Bridget E.
    Neul, Jeffrey L.
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2813 - 2835
  • [4] Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome
    Cuddapah, Vishnu Anand
    Pillai, Rajesh B.
    Shekar, Kiran V.
    Lane, Jane B.
    Motil, Kathleen J.
    Skinner, Steven A.
    Tarquinio, Daniel Charles
    Glaze, Daniel G.
    McGwin, Gerald
    Kaufmann, Walter E.
    Percy, Alan K.
    Neul, Jeffrey L.
    Olsen, Michelle L.
    [J]. JOURNAL OF MEDICAL GENETICS, 2014, 51 (03) : 152 - 158
  • [5] Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study
    Cutri-French, Clare
    Armstrong, Dallas
    Saby, Joni
    Gorman, Casey
    Lane, Jane
    Fu, Cary
    Peters, Sarika U.
    Percy, Alan
    Neul, Jeffrey L.
    Marsh, Eric D.
    [J]. ANNALS OF NEUROLOGY, 2020, 88 (02) : 396 - 406
  • [6] Severity Assessment in CDKL5 Deficiency Disorder
    Demarest, Scott
    Pestana-Knight, Elia M.
    Olson, Heather E.
    Downs, Jenny
    Marsh, Eric D.
    Kaufmann, Walter E.
    Partridge, Carol-Anne
    Leonard, Helen
    Gwadry-Sridhar, Femida
    Frame, Katheryn Elibri
    Cross, J. Helen
    Chin, Richard F. M.
    Parikh, Sumit
    Panzer, Axel
    Weisenberg, Judith
    Utley, Karen
    Jaksha, Amanda
    Amin, Sam
    Khwaja, Omar
    Devinsky, Orrin
    Neul, Jeffery L.
    Percy, Alan K.
    Benke, Tim A.
    [J]. PEDIATRIC NEUROLOGY, 2019, 97 : 38 - 42
  • [7] Detection of neurophysiological features in female R255X MeCP2 mutation mice
    Dong, Hong-Wei
    Erickson, Kirsty
    Lee, Jessica R.
    Merritt, Jonathan
    Fu, Cary
    Neul, Jeffrey L.
    [J]. NEUROBIOLOGY OF DISEASE, 2020, 145
  • [8] Farmer C, 2022, INT REV RES DEV DISA, V62, P1, DOI 10.1016/bs.irrdd.2022.05.001
  • [9] FDA, 2018, Methods to identify what is important to patients & select, develop or modifyfit-for-purpose clinical outcomes assessments
  • [10] FDA, 2020, PAT FOC DRUG DEV COL